GVAX
Navigation Links
GVAX in Medical News
Cell Genesys, Inc. (Nasdaq: CEGE) today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with operable pancreatic cancer who received GVAX after su...
...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...
Experimental Cancer Vaccines Show Promise
...ented Tuesday at the American Association for Cancer Research annual meeting, in San Diego. A second study, out of the Netherlands, found that the gvax vaccine stimulated a significant immune response in men with prostate cancer. Five out of six participants receiving the highest dose of vaccine showe...Immunotherapy: enlisting the immune system to fight cancer
...ic hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilumumab: ...phase I trial, they observed that a combination of gvax immunotherapy with ipilimumab lowered prostate-spe...s. Higher doses of ipilimumab combined with the gvax vaccine is showing a lot of success in increasing ......ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...
Cell Genesys Reports Fourth Quarter and Year-End 2007 Results
... potential association between immune responses to gvax immunotherapy for prostate cancer and increase...irst of two ongoing Phase 3 clinical trials of gvax immunotherapy for prostate cancer, completed a ... Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials ...Combo Treatment Best for Melanoma, Advanced Ovarian Cancer
...ce a protein called GVAX. When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting a more energetic attack o...mune response spurred by the vaccine, researchers studied whether combining gvax vaccines with monoclonal antibody therapy could lengthen remissions and que...Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
... When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting ... researchers have begun studying whether combining gvax vaccines with monoclonal antibody therapy could le... patients who had previously been immunized with a gvax vaccine. The new study, a joint effort of Dana-...GVAX in Medical Technology
SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE ) today reports the results of an analysis
examining the potential association between immune responses to GVAX
immunotherapy for prostate cancer and increased patient survival in a Phase
2 trial i...
Conference Call Scheduled for 10:00 a.m. ET Today SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of...
SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...
SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...
... hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimum...limumab in combination with the Cell Genesys, Inc. gvax immunotherapy for prostate cancer (an investig...nsion cohort (3 mg/kg ipilimumab). The dose of gvax immunotherapy for prostate cancer used in this...
...ed follow-up data from a Phase 2 clinical trial of gvax immunotherapy for pancreatic cancer which was cond...ients with operable pancreatic cancer who received gvax after surgical resection of their tumor and adjuva...ent surgery and adjuvant therapy without receiving gvax indicated that the median overall survival of the ...
Conference Call Scheduled for 10:00 a.m. ET Today SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of...
SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...
SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
...state Cancer Session) -- Oral presentation beginning at 11:30 a.m. local time on Monday, June 2, 2008. -- "Expanded phase 1 combination trial of gvax immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)" (Abstract #5146, Geni...... hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimum...limumab in combination with the Cell Genesys, Inc. gvax immunotherapy for prostate cancer (an investig...nsion cohort (3 mg/kg ipilimumab). The dose of gvax immunotherapy for prostate cancer used in this...
...ed follow-up data from a Phase 2 clinical trial of gvax immunotherapy for pancreatic cancer which was cond...ients with operable pancreatic cancer who received gvax after surgical resection of their tumor and adjuva...ent surgery and adjuvant therapy without receiving gvax indicated that the median overall survival of the ...
GVAX in Biological News
Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
...eration and allows both Tregs and Teff cells to proliferate in response to exposure to self-antigen. Interestingly, combination of CLTA4 blockade with gvax selectively primes the anti-tumor Teff cells for action. This led to greater infiltration of Teff cells into the tumor, and eventually to tumor reject...GVAX in Biological Technology
New Report Just Published: World Prostate Cancer Therapeutics Market Report
...n Bavituximab in Prostate Cancer II-54 Cell Genesys Reveals Data of gvax Immunotherapy for Treatment of Prostate Cancer II-54 Bioponic Phyto...to Take Over Rights of a New Marker Technology II-78 Cell Genesys's gvax Prostate Cancer-Treatment Attains FDA's Fast Track Tag II-78 Envisi...Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
...pril 12-16, 2008 in San Diego: -- "Dendritic and T cell functions in patients with metastatic hormone- refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session) - Oral presentation scheduled for Monday, A...Cell Genesys to Present at the BIO CEO and Investor Conference
...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...Cell Genesys to Webcast Third Quarter 2007 Conference Call
...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...Cell Genesys to Present at the BIO Investor Forum
...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial......c cancer drug market to more than double by 2016. The new Pharmacor report entitled Pancreatic Cancer finds that Pharmexa's GV1001 and Cell Genesys's gvax will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan....
Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...Other TagsTitaniumHumansHumansPolycysticLaughterLasikLasikSuccessSuccessSuccessSuccessOther Contentscloacacloggingcloggingcloggingbankbankbankbankbankbankbankbankcoccicochleacochleacochleacochleacodominantbiasbiasbiasbias
DecreasingMusicalTitaniumHardenedHumansSolariumPeacefulAerobicsMetapneumovirusCultivatingPolycysticLaughterLasikSuccess
(Date:11/27/2009)... Specialist manufacturers who use medical lo... millions of dollars by bringing in technology par...ng numbers of pro-active medical manufacturers are...pt stage of their projects, ensuring that progress...ses or potentially outdated technology. , ...
(Date:11/26/2009)...ars, the number of Americans living with diabetes ...n 2009 to 44.1 million in 2034. Over the same peri...g from $113 billion to $336 billion, even with no ... based at the University of Chicago report in the ...of those with diabetes covered by Medicare will ri...
(Date:11/26/2009)... No more letters from the North Pole, Textsa... messages from Santa , No...perational efficiencies at the North Pole Santa Cl...dren all over the globe informed of his Christmas ...uo;s research department have identified a large a...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offering free na...az and Yasmin birth control pills who have suffere..., Stroke, Heart Attack or other related cardiac is...all toll free at 1-800-856-6405 or go to the firm&...ill out an online case evaluation form. , ...
(Date:11/25/2009)...ALGARY,Nov.25/PRNewswire/-SentinelleMedicalInc.,al...oilsandsoftwareandCalgaryScientificInc.,aleadingpr...dawebversionofAegis(TM)Breast4DAdvancedVisualizati...ttrulyzero-footprintWebclientbasedmedicalimagingof...atformallowsforzero-footprintaccess-requiringnosof...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3[0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells[0] Diabetes cases to double and costs to triple by 2034[1] Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes[0] Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills[1] Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology
(Date:11/26/2009)...aphylococcus Aureus ) and other drug-resistant bac...lasma prototype devices have been developed to off...cktails. , Two prototype devices have been devel...in (e.g. hands and feet) in hospitals and public s... another to shoot bacteria-killing agents into inf...
(Date:11/25/2009)...e easy lives. In addition to mammalian immune syst...es called bacteriophages, viruses that kill half t...acteria and another class of microorganisms called... such as deep-sea volcanic vents) manage just fine...defense system that helps protect them from many v...
(Date:11/25/2009)... Soil is the linchpin of the environment, where at... that, many students see soil as "just dirt" a pl... educators are challenged with the task of helping...portance of soil in the environment. , A collab...teachers at University of Nebraska-Lincoln, Oregon...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3It's not just dirt! 2Scientists find that individuals in vegetative states can learn 9986 1Scientists find that individuals in vegetative states can learn 9986 2REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 1REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 2REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 3Open House For Women With Medically Induced Hair Loss 57709 1Open House For Women With Medically Induced Hair Loss 57709 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |